Features of early-onset familial Alzheimer’s disease
- Авторлар: Cherdantseva Y.E1, Orlova A.S1, Akarachkova E.S.2, Alekseeva A.Y.1, Akulov M.A3, Dadaeva V.A4, Orlov V.A5
-
Мекемелер:
- I.M. Sechenov First Moscow State University (Sechenov University)
- International Society “Stress Under Control"
- N.N. Burdenko NMRC of Neurosurgery
- National Medical Research Center for Preventive Medicine
- PCH № 4 n.a. P.B. Gannushkin of the Moscow Healthcare Department
- Шығарылым: № 14 (2018)
- Беттер: 18-25
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/296499
- DOI: https://doi.org/10.18565/pharmateca.2018.14.18-25
- ID: 296499
Дәйексөз келтіру
Аннотация
Толық мәтін
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Авторлар туралы
Yu. Cherdantseva
I.M. Sechenov First Moscow State University (Sechenov University)
A. Orlova
I.M. Sechenov First Moscow State University (Sechenov University)
Elena Akarachkova
International Society “Stress Under Control"
Email: nevroius@mail.ru
MD, President
A. Alekseeva
I.M. Sechenov First Moscow State University (Sechenov University)
M. Akulov
N.N. Burdenko NMRC of Neurosurgery
V. Dadaeva
National Medical Research Center for Preventive Medicine
V. Orlov
PCH № 4 n.a. P.B. Gannushkin of the Moscow Healthcare Department
Әдебиет тізімі
- Науменко А.А., Громова Д.О., Трофимова Н.В., Преображенская И.С. Диагностика и лечение болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2016;8(4):91-7.
- Panegyres P.K., Chen H.Y., et al. Early-onset Alzheimer's disease: a global cross-sectional analysis. Eur. J. Neurol. 2014;21(9):1149-54.
- Alzheimer's association. URL: https://www.alz.org/. 2018.
- Ватолина М.А. Проблемы оценки смертности от болезни Альцгеймера в России. Здравоохранение Российской Федерации. 2015;59(4):20-4.
- Seltzer B., Sherwin I. A comparison of clinical features in early- and late-onset primary degenerative dementia. One entity or two? Arch. Neurol. 1983;40(3):143-46.
- Dorszewska J., Prendecki M., Oczkowska A., et al. Molecular Basis of Familial and Sporadic Alzheimer's Disease. Curr. Alzh. Res. 2016;13(9):952-63.
- Day G.S., Musiek E.S., Roe C.M., et al. Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA. Neurol. 2016;73(9):1125-32.
- Abbate C., Arosio B., Cantatore A., et al. Familial late-onset Alzheimer's disease: description of an Italian family with four affected siblings and one case of early-onset dementia in the preceding generation. Aging. Clin. Exp. Res. 2016;28(5):991-95.
- Shea Y.F., Chu L.W., Chan A.O., et al. A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J. Formos. Med. Assoc. 2016;115(2):67-75.
- Dai M.H., Zheng H., Zeng L.D., Zhang Y The genes associated with early-onset Alzheimer's disease. Oncotarget. 2017;15:15132-43.
- Wu L., Rosa-Neto P., Hsiung G.Y., et al. Early-onset familial Alzheimer's disease (EOFAD). Can. J. Neurol. Sci. 2012;39(4):436-45.
- Müller S., Preische O., Sohrabi H.R., et al. Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzh. Dement. 2018;21:1552-60.
- Niu F., Yu S., Zhang Z., et al. Novel mutation in the PSEN2 gene (N141Y) associated with early-onset autosomal dominant Alzheimer's disease in a Chinese Han family. Neurobiol. Aging. 2014;35(10):2420.
- Яузина Н.А., Комлева Ю.К., Салмина А.Б. и др. Эпидемиология болезни Альцгеймера в мире. Неврологический журнал. 2012;17:32-7. [Yauzina N.A., Komleva Yu.K., Salmina A.B., et al. Epidemiology of Alzheimer's disease in the world. Nevrologicheskiizhurnal. 2012;17:32-7. (in Russ.)].
- Гаврилова С.И., Колыхалов И.В. Разработка стандарта терапии болезни Альцгеймера. Современная терапия в психиатрии и неврологии. 2012;1:5-
- [Gavrilova S.i., Kolykhalov i.V. Development of a standard Alzheimer's disease therapy. Sovremennaya terapiya v psikhiatrii i nevrologii. 2012;1:5-10. (in Russ.)].
- Wu L., Rosa-Neto P., Hsiung G.Y., et al. Early-onset familial Alzheimer's disease (EOFAD). Can. J. Neurol. Sci. 2012;39(4):436-45.
- Cacace R., Sleegers K., Van Broeckhoven C. Molecular genetics of early-onset Alzheimer's disease revisited. Alzh. Dement. 2016;12(6):733-48.
- Колыхалов И.В. Некогнитивные психические расстройства при болезни Альцгеймера: эпидемиологические, клинико-психопатологические, прогностические и терапевтические аспекты. Дисс. докт. мед. наук. М., 2016.
- Белоусов Ю.Б., Зырянов С.К., Белоусов Д.Ю., Бекетов А.С. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клиническая практика. 2009;1:3-
- Комлева Ю.К., Кувачева Н.В., Лопатина О.Л. Современные представления о патогенезе болезни Альцгеймера: новые подходы к фармакотерапии (обзор). Современные технологии в медицине. 2015;7(3):138-48.
- Hersi M., Irvine B., Gupta P., et al. Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. Neurotoxicol. 2017;6:143-87.
- Wingo T.S., Lah J.J., Levey A.I., Cutler D.J. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch. Neurol. 2012;69:59-64.
- Jarmolowicz A.I., Chen H.Y., Panegyres P.K. The Patterns of Inheritance in Early-Onset Dementia: Alzheimer's Disease and Frontotemporal Dementia. Am. J. Alzh. Dis. Other Demen. 2014;30:299-306.
- Janssen J.C., Beck J.A., Campbell T.A., et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurol. 2003;60:235-39.
- Alzforum networking for a cure. URL: https://www. alzforum.org/mutations. 2018.
- Ikeuchi T., Kaneko H., Miyashita A., et al. Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement. Geriatr. Cogn. Disord. 2008;26:43-9.
- Barber I.S., Braae A., Clement N., et al. Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiol. Aging. 2017;49:215.
- Lanoiselée H.M., Nicolas G., Wallon D., et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS. Med. 2017;14(3):e1002270.
- Shao W., Peng D., Wang X. Genetics of Alzheimer's disease: From pathogenesis to clinical usage. J. Clin. Neurosci. 2017;45:1-8.
- Liu C.C., Liu C.C., Kanekiyo T., et al. Apolipoprotein E. and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9(2):106-18.
- Alzheimer's Association. Alzheimer's disease facts and figures. Alzh. Dement. 2016;12(4):459-509.
- Rajah M.N., Wallace L.M.K., Ankudowich E., et al. Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife. Neuroimage Clin. 2017;14:760-74.
- Zhu J.B., Tan C.C., Tan L., Yu J.T. State of Play in Alzheimer's Disease Genetics. J. Alzh. Dis. 2017;58(3):631-59.
- Butters M.A., Sweet R.A., Mulsant B.H., et al. APOE is associated with age-of-onset, but not cognitive functioning, in late-life depression. Int. J. Geriatr. Psychiatry. 2003;18(1):1075-81.
- Bateman R.J., Aisen P.S., De Strooper B., et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzh. Res. Ther. 2011;2:35.
- Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzh. Dement. 201;7:270-79.
- McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzh. Dement. 2011;7:263-69.
- Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzh. Dement. 2011;7:280-92.
- De la Torre J.C. Three postulates to help identify the cause of Alzheimer's disease. J. Alzh. Dis. 2011;24:657-68.
- Glass C.K., Saijo K., Winner B., et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-34.
- Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Sci. 2002;297:353-56.
- Bettens K., Sleegers K., Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum. Mol. Genet. 2010;19:4-11.
- Esler W.P., Wolfe M.S. A portrait of Alzheimer secretases - new features and familiar faces. Sci. 2001;293:1449-54.
- Citron M., Oltersdorf T., Haass C., et al. Mutation of the beta-amyloid precursor protein in familial Alzheimers-disease increases betaprotein production. Nature. 1992;360:672-74.
- Suzuki N., Cheung T.T., Cai X.D., et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Sci. 1994;26:1336-40.
- Steiner H. Uncovering gamma-secretase. Curr. Alzh. Res. 2004;1:175-81.
- Преображенская И.С. Современные подходы к диагностике и лечению болезни Альцгеймера. Медицинский совет. 2017;10:26-31.
- Jan A.T., Azam M., Rahman S., et al. Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update. Front Aging Neurosci. 2017;9:356.
- Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 2001;32(5):367-81.
- Freudenberg-Hua Y., Li W., Davies P. The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. Front. Med. (Lausanne). 2018;5:108.
- Kong D., Giovanello K.S., Wang Y., et al. Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data. J. Alzh. Dis. 2015;46(3):695-702.
- Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. 3-е изд. Руководство для врачей. М., 2011. 272 с.
- Науменко А.А., Вахнина Н.В. Болезнь Альцгеймера под маской инсульта. Неврология, нейропсихиатрия, психосоматика 2016;8(2):100-6.
- Penninkilampi R., Brothers H.M., Eslick G.D. Safety and Efficacy of Anti-Amyloid-ß Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. J. Neuroimmune Pharmacol. 2017;12(1):194-203.
- Wang C.H., Wang L.S., Zhu N. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses. Eur. Rev. Med. Pharmacol. Sci. 2016;20(22):4801-17.
- Matsunaga S., Kishi T., Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2014;28:1-11.
- Matsunaga S., Kishi T., Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS. One. 2015;10(4):e0123289.
- Kishi T, Matsunaga S., Oya K., et al. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. J. Alzh. Dis. 2017;60(2): 401-25.
- Jiang J., Jiang H. Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. Neurol. Sci. 2015;36(9):1633-41.
- Liu C.S., Ruthirakuhan M., Chau S.A., et al. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. Curr. Alzh. Res. 2016;13(10):1134-44.
- Panza F., Solfrizzi V., Imbimbo B.P., et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Exp. Rev. Clin. Immunol. 2014;10(3):405-19.
- Lannfelt L., Relkin N.R., Siemers E.R. Amyloid-β-directed immunotherapy for Alzheimer's disease. J. Intern. Med. 2014;275(3):284-95.
- Panza F., Solfrizzi V., Imbimbo B.P., et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Exp. Rev. Neurother. 2014;14(9):973-86.
- Ostrowitzki S., Lasser R.A., Dorflinger E., et al. A phase III randomized trial of gacntenerumab in prodromal Alzheimer's disease. Alzh. Res. Ther. 2017;9(1):95.
Қосымша файлдар
![](/img/style/loading.gif)